A Dilemma in the Glycosaminoglycan-Based Therapy: Synthetic or Naturally Unique Molecules?

Medicinal Research Reviews

Volumn 35, Issue 6, 2015, Pages 1195-1219

  Pomin, Vitor H ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Carbohydrate based drugs; Chemical synthesis, drug development; Enzymatic synthesis; Glycosaminoglycans; Oligosaccharide synthesis

Indexed keywords

GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN POLYSULFATE; OLIGOSACCHARIDE;

ARTICLE; ASCIDIACEA; BIVALVE; CARBOHYDRATE SYNTHESIS; CRUSTACEA; DRUG SYNTHESIS; ENZYME SYNTHESIS; FUCOSYLATION; GASTROPOD; NONHUMAN; SEA CUCUMBER; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; SYNTHESIS;

ANIMALS; GLYCOSAMINOGLYCANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84943581541     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21356     Document Type: Article

References (128)

1. Sasisekharan R, Venkataraman, G. Heparin and heparan sulfate: Biosynthesis, structure and function. Curr Opin Chem Biol 2000;4:626-631.
2. Rabestein DL. Heparin and heparan sulfate: Structure and function. Nat Prod Rep 2002;19:312-331.
3. Sugahara K, Mikami T, Uyama T, Mizuguchi S, Nomura K, Kitagawa H. Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate. Curr Opin Struct Biol 2003;13:612-620.
4. Funderburgh JL. Keratan sulfate: Structure, biosynthesis, and function. Glycobiology 2000;10:951-958.
5. Pomin, VH. Keratan sulfate: An up-to-date review. Int J Biol Macromol 2015;72:282-289.
6. Almond A. Hyaluronan. Cell Mol Life Sci 2007;64:1591-1596.
7. Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008;72:455-482.
8. Volpi N. Therapeutic applications of glycosaminoglycans. Curr Med Chem 2006;13:1799-17810.
9. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018.
10. McRae SJ, Ginsberg JS. Treatment of venous thromboembolism. Initial treatment of venous thromboembolism. Circulation 2004;110:I-3-I-9.
11. Pomin VH, Piquet AA, Pereira MS, Mourão PA. Residual keratan sulfate in chondroitin sulfate formulations for oral administration. Carbohydr Polym 2012;90:839-846.
12. Esko JD, Kimata K, Lindahl U. Proteoglycans and sulfated glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, Eds. Essentials of Glycobiology, 2nd edition. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009. Chapter 16. Available from http://www.ncbi.nlm.nih.gov/books/NBK1900/
13. Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater 2011;23:H41-H56.
14. Pomin VH. NMR chemical shifts in structural biology of glycosaminoglycans. Anal Chem 2014;86:65-94.
15. Warkentin TE. Heparin-induced thrombocytopenia: A clinicopathologic genesis. Thromb Haemost 1999;82:439-447.
16. Visentin GP. Heparin-induced thrombocytopenia: Molecular pathogenesis. Thromb Haemost 1999;82:448-156.
17. Kelton, JG. Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980;17:259-379.
18. Kakkar VV, Kakkar S, Sanderson RM, Peers CE. Efficacy and safety of two regimens of low molecular weight heparin fragment Fragmin in preventing post-operative venous thromboembolism. Haemostasis 1986;16:19-24.
19. Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med 1989;87:53S-60S.
20. Nishino T, Fukuda A, Nagumo T, Fujihara M, Kaji E. Inhibition of the generation of thrombin and factor Xa by a fucoidan from the brown seaweed Ecklonia kurome. Thromb Res 1999;96:37-49.
21. Liaw PCY, Becker DJ, Stafford AR, Fredenburgh JC, Weitz JI. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 2001; 276:20959-20965.
22. Santos GR, Tovar AM, Capillé NV, Pereira MS, Pomin VH, Mourão PA. Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs. Drug Discov Today 2014;19:1801-1807.
23. Valenstein PN, Walsh MK, Meier F, College of American Pathologists. Heparin monitoring and patient safety: a College of American Pathologists Q-Probes study of 3431 patients at 140 institutions. Arch Pathol Lab Med 2004;128:397-402.
24. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-2467.
25. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008;26:669-675.
26. Larive CK. New developments in the characterization of heparin and its impurities. Anal Bioanal Chem 2011;399:525-526.
27. Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Prod Rep 2012;26:313-321.
28. Laurencin CT, Nair L. The FDA and safety-Beyond the heparin crisis. Nat Biotechnol 2008;26:621-623.
29. Lavine G. Tainted heparin crisis tested FDA's investigative skills. Am J Health Syst Pharm 2009;66:210-211.
30. Sasisekharan R, Shriver Z. From crisis to opportunity: A perspective on the heparin crisis. Thromb Haemost 2009;102;854-858.
31. Rosania L. Heparin crisis 2008: A tipping point for increased FDA enforcement in the pharma sector? Food Drug Law J 2010;65:489-501.
32. Werz DB, Seeberger PH. Carbohydrates as the next frontier in pharmaceutical research. Chem Eur J 2005;11:3194-3206.
33. Seeberger PH, Werz DB. Automated synthesis of oligosaccharides as a basis for drug discovery. Nat Rev Drug Discov 2005;4:751-763.
34. Boltje TJ, Buskas T, Boons GJ. Opportunities and challenges in synthetic oligosaccharide and glycoconjugate research. Nat Chem 2009;1:611-622.
35. Yin J, Eller S, Collot M, Seeberger PH. Acylsulfonamide safety-catch linker: Promise and limitations for solid-phase oligosaccharide synthesis. Beilstein J Org Chem 2012;8:2067-2071.
36. Prudden AR, Chinoy ZS, Wolfert MA, Boons GJ. A multifunctional anomeric linker for the chemoenzymatic synthesis of complex oligosaccharides. Chem Commun 2014;50:7132-7135.
37. Schmaltz RM, Hanson SR, Wong CH. Enzymes in the synthesis of glycoconjugates. Chem Rev 2011;111:4259-4307.
38. Karst NA, Linhardt RJ. Recent chemical and enzymatic approaches to the synthesis of glycosaminoglycans oligosaccharides. Curr Med Chem 2003;10:1993-2031.
39. Avci FY, DeAngelis PL, Liu J, Linhardt RJ. Chapter 15-Enzymatic synthesis of glycosaminoglycans: Improving on nature. Front Mod Carb Chem 2007;960:253-284.
40. DeAngelis PL, Liu J, Linhardt RJ. Chemoenzymatic synthesis of glycosaminoglycans: Re-creating, re-modeling and re-designing naturés longest or most complex carbohydrate chains. Glycobiology 2013;23:764-777.
41. Liu J, Linhardt RJ. Chemoenzymatic synthesis of heparan sulfate and heparin. Nat Prod Rep 2014;31:129-157.
42. Haller M, Boons GJ. Towards a modular approach for heparin synthesis. J Chem Soc Perkin Trans 1 2001; 814-822.
43. Haller MF, Boons GJ. Selectively protected disaccharide building blocks for modular synthesis of heparin fragments. Eur J Org Chem 2002;2002:2033-2038.
44. Lohman GJS, Hunt DK, Högermeier JA, Seeberger PH. Synthesis of iduronic acid building blocks for the modular assembly of glycosaminoglycans. J Org Chem 2003;68:7559-7561.
45. Orgueira HA, Batolozzi A, Schell P, Litjens REJN, Palmacci ER, Seeberger PH. Modular synthesis of heparin oligosaccharides. Chem Eur J 2003;9:140-149.
46. Lohman GJS, Seeberger PH. A stereochemical surprise at the late stage of the synthesis of fully N-differentiated heparin oligosaccharides containing amino, acetamino, and N-sulfonate groups. J Org Chem 2004;69:4081-4093.
47. Noti C, Seeberger PH. Chemical approaches to define the structure-activity relationship of heparin-like glycosaminoglycans. Chem Biol 2005;12:731-756.
48. de Kort M, Buijsman RC, van Boeckel CA. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov Today 2005;10:769-779.
49. de Paz JL, Noti C, Seeberger PH. Microarrays of synthetic heparin oligosaccharides. J Am Chem Soc 2006;128:2766-2767.
50. Noti C, dePaz JL, Polito L, Seeberger PH. Preparation and use of microarrays containing synthetic heparin oligosaccharides for the rapid analysis of heparin-protein interactions. Chem Eur J 2006;12:8664-8666.
51. dePaz JL, Noti C, Böhm F, Werner S, Seeberger PH. Potentiation of fibroblast growth factor activity by synthetic heparin oligosaccharide glycodendrimers. Chem Biol 2007;14:879-887.
52. Adibekian A, Bindschädler P, Timmer MSM, Noti C, Schützenmeister N, Seeberger PH. De novo synthesis of uronic acid building blocks for assembly of heparin oligosaccharides. Chem Eur J 2007;13:4510-4522.
53. Zhang Z, McCallum SA, Xie J, Nieto L, Corzana F, Jiménez-Barbero J, Chen M, Liu J, Linhardt RJ. Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc 2008;130:12998-13007.
54. Peterson S, Frick A, Liu J. Design of biologically active heparan sulfate and heparin using an enzyme-based approach. Nat Prod Rep 2009;26:610-627.
55. Xu Y, Pempe EH, Liu J. Chemoenzymatic synthesis of heparin oligosaccharides with both anti-Xa and anti-IIa activities. J Biol Chem 2012;287:29054-29061.
56. Li P, Sheng J, Liu Y, Li J, Liu J, Wang F. Heparosan-derived heparan sulfate/heparin-like compounds: one kind of potential therapeutic agents. Med Res Rev 2013;3:665-692.
57. Nonaka M, Bao X, Matsumura F, Götze S, Kandasamy J, Kononov A, Broide DH, Nakayama J, Seeberger PH, Fukuda M. Synthetic di-sulfated iduronic acid attenuates asthmatic response by blocking T-cell recruitment to inflammatory sites. Proc Natl Acad Sci USA 2014;111:8173-8178.
58. Prabhu A, Venot A, Boons GJ. New set of orthogonal protecting groups for the modular synthesis of heparan sulfate fragments. Org Lett 2003;5:4975-4978.
59. Arungundram S, Al-Mafraji K, Asong J, Leach FE, Amster IJ, Venot A, Turnbull JE, Boons GJ. Modular synthesis of heparan sulfate oligosaccharides for structure-activity relationship studies. J Am Chem Soc 2009;131:17394-17405.
60. Liu R, Xu Y, Chen M, Weïwer M, Zhou X, Bridges AS, DeAngelis PL, Zhang Q, Linhardt RJ, Liu J. Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem 2010;285:34240-34249.
61. Nguyen TKN, Arungundram S, Tran VM, Raman K, Al-Mafraji K, Venot A, Boons GJ, Kuberan B. A synthetic heparan sulfate oligosaccharide library reveals the novel enzymatic action of D-glucosaminyl 3-O-sulfotransferase-3a. Mol Biosyst 2012;8:609-614.
62. Leach III FE, Arungundram S, Al-Mafraji K, Venot A, Boons GJ, Amster IJ. Electron detachment dissociation of synthetic heparan sulfate glycosaminoglycans tetrasaccharides varying in degree of sulfation and hexuronic acid stereochemistry. Int J Mass Spectrom 2012;330-332:152-159.
63. Zong C, Venot A, Dhamale O, Boons GJ. Fluorous supported modular synthesis of heparan sulfate oligosaccharides. Org Lett 15:342-345.
64. Hsieh PH, Xu Y, Keire DA, Liu J. Chemoenzymatic synthesis and structural characterization of 2-O-sulfated glucuronic acid-containing heparan sulfate hexasaccharides. Glycobiology 2014;24:681-692.
65. Dhamale OP, Zong C, Al-Mafraji K, Boons GJ. New glucuronic acid donors for the modular synthesis of heparan sulfate oligosaccharides. Org Biomol Chem 2014;12:2087-2098.
66. Cai C, Dickinson DM, Li L, Masuko S, Suflita M, Schultz V, Nelson SD, Bhaskar U, Liu J, Linhardt RJ. Fluorous-assisted chemoenzymatic synthesis of heparan sulfate oligosaccharides. Org Lett 2014;16:2240-2243.
67. Eller S, Collot M, Yin J, Hahm HS, Seeberger PH. Automated solid-phase synthesis of chondroitin sulfate glycosaminoglycans. Angew Chem Int Ed 2013;52:5858-5861.
68. Liang CF, Hahm HS, Seeberger PH. Automated synthesis of chondroitin sulfate oligosaccharides. Methods Mol Biol 2015;1229:3-10.
69. Kandasamy J, Schuhmacher F, Hahm HS, Klein JC, Seeberger PH. Modular automated solid phase synthesis of dermatan sulfate oligosaccharides. Chem Commun 2014;50:1875-1877.
70. Giji S, Arumugam M. Isolation and characterization of hyaluronic acid from marine organisms. Adv Food Nutr Res 2014;72:61-77.
71. Kanchana S, Arumugam M, Giji S, Balasubramanian T. Isolation, characterization and antioxidant activity of hyaluronic acid from marine bivalve mollusc Amussium pleuronectus (Linnaeus, 1758). Bioactive Carbohydr Diet Fibre 2013;2:1-7.
72. Vázquez JA, Rodríguez-Amado I, Montemayor MI, Fraguas J, González Mdel P, Murado MA. Chondroitin sulfate, hyaluronic acid and chitin/chitosan production using marine waste sources: Characteristics, applications and eco-friendly processes: A review. Mar Drugs 2013;11:747-774.
73. Ito M, Kitamikado M, Yamagata T. Isolation and characterization of an asparagine-linked keratan sulfate from the skin of a marine teleost, Scomber japonicus. Biochim Biophys Acta 1984;797:221-230.
74. Gomes AM, Kozlowski EO, Pomin VH, de Barros CM, Zaganeli JL, Pavão MS. Unique extracellular matrix heparan sulfate from the bivalve Nodipecten nodosus (Linnaeus, 1758) safely inhibits arterial thrombosis after photochemically induced endothelial lesion. J Biol Chem 2010;285:7312-7323.
75. Brito AS, Cavalcante RS, Palhares LC, Hughes AJ, Andrade GP, Yates EA, Nader HB, Lima MA, Chavante SF. A non-hemorrhagic hybrid heparin/heparan sulfate with anticoagulant potential. Carbohydr Polym 2014;99:372-378.
76. Wang H, Toida T, Kim YS, Capila I, Hileman RE, Bernfield M, Linhardt RJ. Glycosaminoglycans can influence fibroblast growth factor-2 mitogenicity without significant growth factor binding. Biochem Biophys Res Commun 1997;235:369-373.
77. Vieira TC, Costa-Filho A, Salgado NC, Allodi S, Valente AP, Nasciutti LE, Silva LC. Acharan sulfate, the new glycosaminoglycan from Achatina fulica Bowdich 1822. Structural heterogeneity, metabolic labeling and localization in the body, mucus and the organic shell matrix. Eur J Biochem 2004;271:845-854.
78. Arumugam M, Garg H, Ajithkumar T, Shanmugam A. Antiproliferative heparin (glycosaminoglycans) isolated from giant clam (Tridacna maxima) and green mussel (Perna viridis). Afr J Biotechnol 2009;8:2394-2396.
79. Gomes AM, Kozlowski EO, Borsig L, Teixeira FC, Vlodavsky I, Pavão MS. Antitumor properties of a new non-anticoagulant heparin analog from the mollusk Nodipecten nodosus: Effect on P-selectin, heparanase, metastasis and cellular recruitment. Glycobiology 2015;25:386-393.
80. Chavante SF, Brito AS, Lima M, Yates E, Nader H, Guerrini M, Torri G, Bisio A. A heparin-like glycosaminoglycan from shrimp containing high levels of 3-O-sulfated D-glucosamine groups in an unusual trisaccharide sequence. Carbohydr Res 2014;390:59-66.
81. Li DW, Lee IS, Sim JS, Toida T, Linhardt RJ, Kim YS. Long duration of anticoagulant activity and protective effects of acharan sulfate in vivo. Thromb Res 2004;113:67-73.
82. Wu SJ, Chun MW, Shin KH, Toida T, Park Y, Linhardt RJ, Kim YS. Chemical sulfonation and anticoagulant activity of acharan sulfate. Thromb Res 1998;92:273-281.
83. Ghosh AK, Hirasawa N, Lee YS, Kim YS, Shin KH, Ryu N, Ohuchi K. Inhibition by acharan sulphate of angiogenesis in experimental inflammation models. Br J Pharmacol 2002;137:441-448.
84. Shim JY, Lee YS, Jung SH, Choi HS, Shin KH, Kim YS. Pharmacological activities of a new glycosaminoglycan, acharan sulfate isolated from the giant African snail Achatina fulica. Arch Pharm Res 2002;25:889-894.
85. Lee YS, Yang HO, Shin KH, Choi HS, Jung SH, Kim YM, Oh DK, Linhardt RJ, Kim YS. Suppression of tumor growth by a new glycosaminoglycan isolated from the African giant snail Achatina fulica. Eur J Pharmacol 2003;465:191-198.
86. Joo EJ, ten Dam GB, vanKuppevelt TH, Toida T, Linhardt RJ, Kim YS. Nucleolin: Acharan sulfate-binding protein on the surface of cancer cells. Glycobiology 2005;15:1-9.
87. Joo EJ, Yang H, Park Y, Park NY, Toida T, Linhardt RJ, Kim YS. Induction of nucleolin translocation by acharan sulfate in A549 human lung adenocarcinoma. J Cell Biochem 2010;110:1272-1278.
88. Sim JS, Hahn BS, Im AR, Park Y, Shin JE, Bae EA, Kim DH, Kim YS. Inhibition of Helicobacter pylori adhesion to Kato III cells by intact and low molecular weight acharan sulfate. Glycoconj J 2011;28:411-418.
89. Im AR, Kim JY, Kim HS, Cho S, Park Y, Kim YS. Wound healing and antibacterial activities of chondroitin sulfate- and acharan sulfate-reduced silver nanoparticles. Nanotechnology 2013;24:395102.
90. Kim HS, Lee YH, Lee YR, Im SA, Lee JK, Kim YS, Sim JS, Choi HS, Lee CK. Activation of professional antigen presenting cells by acharan sulfate isolated from giant African snail, Achatina fulica. Arch Pharm Res 2007;30:866-870.
91. Park Y. Mining invertebrate natural products for future therapeutic treasure. Nat Prod Commun 2011;6:1403-1408.
92. Vieira RP, Mourão PA, Occurrence of a unique fucose-branched chondroitin sulfate in the body wall of a sea cucumber. J Biol Chem 1988;263:18176-18183.
93. Vieira RP, Mulloy B, Mourão PA. Structure of a fucose-branched chondroitin sulfate from sea cucumber. Evidence for the presence of 3-O-sulfo-beta-D-glucuronosyl residues. J Biol Chem 1991;266:13530-13536.
94. Mourão PA, Pereira MS, Pavão MS, Mulloy B, Tollefsen DM, Mowinckel MC, Abildgaard U. Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action. J Biol Chem 1996;271:23973-23984.
95. Fonseca RJ, Santos GR, Mourão PA. Effects of polysaccharides enriched in 2, 4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications. Thromb Haemost 2009;102:829-836.
96. Pomin, VH. Holothurian fucosylated chondroitin sulfate. Mar Drugs 2014;12:232-254.
97. Chen S, Xue C, Yin L, Tang Q, Yu G, Chai W. Comparison of structures and anticoagulant activities of fucosylated chondroitin sulfates from different sea cucumbers. Carbohydr Polym 2011;83:688-696.
98. Fonseca RJ, Oliveira SN, Pomin VH, Mecawi AS, Araujo IG, Mourão PA. Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Challenges for the study of anticoagulant polysaccharides. Thromb Haemost 2010;103:994-1004.
99. Wu M, Wen D, Gao N, Xiao C, Yang L, Xu L, Lian W, Peng W, Jiang J, Zhao J. Anticoagulant and antithrombotic evaluation of native fucosylated chondroitin sulfates and their derivatives as selective inhibitors of intrinsic factor Xase. Eur J Med Chem 2015;92:257-269.
100. Mourão PA, Guimarães B, Mulloy B, Thomas S, Gray E. Antithrombotic activity of a fucosylated chondroitin sulphate from echinoderm: Sulphated fucose branches on the polysaccharide account for its antithrombotic action. Br J Haematol 1998;101:647-652.
101. Pacheco RG, Vicente CP, Zancan P, Mourão PA. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coagul Fibrinol 2000;11:563-573.
102. Mourão PA. Use of sulfated fucans as anticoagulant and antithrombotic agents: Future perspectives. Curr Pharm Des 2004;10:967-981.
103. Zancan P, Mourão PA. Venous and arterial thrombosis in rat models: Dissociation of the antithrombotic effects of glycosaminoglycans. Blood Coagul Fibrinol 2004;15:45-54.
104. Fonseca RJ, Mourão PA. Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Thromb Haemost 2006;96:822-829.
105. Minamiguchi K, Kitazato KT, Nagase H, Sasaki E, Ohwada K, Kitazato K. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model. Kidney Intern 2003;63:1548-1555.
106. Tovar AM, Mourão PA. High affinity of a fucosylated chondroitin sulfate for plasma low density lipoprotein. Atherosclerosis 1996;26:85-195.
107. Igarashi M, Takeda Y, Mori S, Takahashi K, Fuse T, Yamamura M, Saito Y. Depolymerized holothurian glycosaminoglycan (DHG) prevents neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 1997;129:27-31.
108. Tapon-Bretaudière J, Drouet B, Matou S, Mourão PA, Bros A, Letourneur D, Fischer AM. Modulation of vascular human endothelial and rat smooth muscle cell growth by a fucosylated chondroitin sulfate from echinoderm. Thromb Haemost 2000;84:332-337.
109. Tapon-Bretaudière J, Chabut D, Zierer M, Matou S, Helley D, Bros A, Mourão PA, Fischer AM. A fucosylated chondroitin sulfate from echinoderm modulates in vitro fibroblast growth factor 2-dependent angiogenesis. Mol Cancer Res 2002;1:96-102.
110. Melo-Filho NM, Belmiro CL, Gonçalves RG, Takiya CM, Leite MJ, Pavão MS, Mourão PA. Fucosylated chondroitin sulfate attenuates renal fibrosis in animals submitted to unilateral ureteral obstruction: A P-selectin-mediated event? Am J Physiol Renal Physiol 2010;299:F1299-F1307.
111. Borsig L, Wang L, Cavalcante MC, Cardilo-Reis L, Ferreira PL, Mourão PA, Esko JD, Pavão MS. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem 2007;282:14984-14991.
112. Lian W, Wu M, Huang N, Gao N, Xiao C, Li Z, Zhang Z, Zheng Y, Peng W, Zhao J. Anti-HIV-1 activity and structure-activity-relationship study of a fucosylated glycosaminoglycan from an echinoderm by targeting the conserved CD4 induced epitope. Biochim Biophys Acta 2013;1830:4681-4691.
113. Huang N, Wu MY, Zheng CB, Zhu L, Zhao JH, Zheng YT. The depolymerized fucosylated chondroitin sulfate from sea cucumber potently inhibits HIV replication via interfering with virus entry. Carbohydr Res 2013;380:64-69.
114. Hu S, Chang Y, Wang J, Xue C, Shi D, Xu H, Wang Y. Fucosylated chondroitin sulfate from Acaudina molpadioides improves hyperglycemia via activation of PKB/GLUT4 signaling in skeletal muscle of insulin resistant mice. Food Funct 2013;4:1639-1646.
115. Bastos MF, Albrecht L, Kozlowski EO, Lopes SC, Blanco YC, Carlos BC, Castiñeiras C, Vicente CP, Werneck CC, Wunderlich G, Ferreira MU, Marinho CR, Mourão PA, Pavão MS, Costa FT. Fucosylated chondroitin sulfate inhibits Plasmodium falciparum cytoadhesion and merozoite invasion. Antimicrob Agents Chemother 2014;58:1862-1871.
116. Gomes CL, Leão CL, Venturotti C, Barreira AL, Guimarães G, Fonseca RJ, Fortunato RS, Mourão PA, Delgado AG, Takiya CM, Leite MJ. The protective role of fucosylated chondroitin sulfate, a distinct glycosaminoglycan, in a murine model of streptozotocin-induced diabetic nephropathy. PLoS One 2014;9:e106929.
117. Yoshida HI, Minami Y. Structure of DHG, a depolymerized holothurian glycosaminoglycan from sea cucumber, Stichopus japonicus. Tetrahedron Lett 1992;33:4959-4962.
118. Pomin VH. Sea, carbohydrates and clotting: A triad on the road of drug discovery. Mini Rev Med Chem 2014;14:717-724.
119. Chen S, Li G, Wu N, Guo X, Liao N, Ye X, Liu D, Xue C, Chai W. Sulfation pattern of the fucose branch is important for the anticoagulant and antithrombotic activities of fucosylated chondroitin sulfates. Biochim Biophys Acta 2013;1830:3054-3066.
120. Luo L, Wu M, Xu L, Lian W, Xiang J, Lu F, Gao N, Xiao C, Wang S, Zhao J. Comparison of physicochemical characteristics and anticoagulant activities of polysaccharides from three sea cucumbers. Mar Drugs 2013;11:399-417.
121. Ye L, Xu L, Li J. Preparation and anticoagulant activity of a fucosylated polysaccharide sulfate from a sea cucumber Acaudina molpadioidea. Carbohydr Polym 2012;87:2052-2057.
122. Wu M, Huang R, Wen D, Gao N, He J, Li Z, Zhao J. Structure and effect of sulfated fucose branches on anticoagulant activity of the fucosylated chondroitin sulfate from sea cucumber Thelenata ananas. Carbohydr Polym 2012;87:862-868.
123. Nagase H, Enjyoji KI, Minamiguchi K, Kitazato KY, Kitazato K, Saito H, Kato H. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: Antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Blood 1995;5:1527-1534.
124. Pavão MS, Aiello KR, Werneck CC, Silva LC, Valente AP, Mulloy B, Colwell NS, Tollefsen DM, Mourão PA. Highly sulfated dermatan sulfates from Ascidians. Structure versus anticoagulant activity of these glycosaminoglycans. J Biol Chem 1998;273:27848-27857.
125. Pavão MS, Mourão PA, Mulloy B, Tollefsen DM. A unique dermatan sulfate-like glycosaminoglycan from ascidian. Its structure and the effect of its unusual sulfation pattern on anticoagulant activity. J Biol Chem 1995;270:31027-31036.
126. Pavão MS. Structure and anticoagulant properties of sulfated glycosaminoglycans from primitive Chordates. An Acad Bras Cienc 2002;74:105-112.
127. Vicente CP, Zancan P, Peixoto LL, Alves-Sá R, Araújo FS, Mourão PA, Pavão MS. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding. Thromb Haemost 2001;86:1215-1220.
128. Kozlowski EO, Pavao MS, Borsig L. Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. J Thromb Haemost 2011;9:1807-1815.